Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201033 | 0.87 | TRPA1 (0.36) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL1200837 | 0.78 | TRPA1 (0.39) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL1200540 | 0.75 | TRPA1 (0.39) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL1200657 | 0.73 | TRPA1 (0.35) | TRPA1TSHRALDH1A1NPC1POLB | |
| SCHEMBL1199568 | 0.72 | TRPA1 (0.43) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL1200819 | 0.71 | TRPA1 (0.42) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL27836981 | 0.71 | TSHR (0.42) | TRPA1TSHRPBRM1LMNAPOLB | |
| SCHEMBL1200547 | 0.71 | TSHR (0.42) | TRPA1TSHRPBRM1LMNAPOLB | |
| Pentane SCHEMBL28983044 | 0.70 | TRPA1 (0.38) | TRPA1TSHRALDH1A1HPGDPBRM1 | |
| SCHEMBL1200534 | 0.70 | L3MBTL1 (0.37) | TSHRALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309753-B2 | Method for producing optically active cyanohydrin compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264005-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034718-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN COMPOUND | CBR3, ACSL3, CCNL2 | TRPA1 1105/4885TSHR 4501/4885ALDH1A1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.